Literature DB >> 15834843

The effect of nabilone on neuropsychological functions related to driving ability: an extended case series.

Ilsemarie Kurzthaler1, Thomas Bodner, Georg Kemmler, Tanja Entner, Joerg Wissel, Thomas Berger, W Wolfgang Fleischhacker.   

Abstract

The primary goal of this prospective extended case series was to obtain the first data about the potential influence of nabilone intake on driving ability related neuropsychological functions. Six patients were investigated within a placebo controlled, double-blind crossover study of this synthetic cannabinoid (2 mg/day) in patients with multiple sclerosis and spasticity associated pain. Five neuropsychological functions (reaction time, working memory, divided attention, psychomotor speed and mental flexibility) were assessed. No indication was found of a deterioration of any of the five investigated neuropsychological functions during the 4-week treatment period with nabilone. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834843     DOI: 10.1002/hup.688

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  6 in total

1.  Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2011-01-11       Impact factor: 4.492

2.  Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial.

Authors:  Jörg Wissel; Tanja Haydn; Jörg Müller; Christian Brenneis; Thomas Berger; Werner Poewe; Ludwig D Schelosky
Journal:  J Neurol       Date:  2006-09-20       Impact factor: 4.849

Review 3.  Role of cannabinoids in multiple sclerosis.

Authors:  John P Zajicek; Vicentiu I Apostu
Journal:  CNS Drugs       Date:  2011-03       Impact factor: 5.749

Review 4.  Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations.

Authors:  Meldon Kahan; Anita Srivastava; Sheryl Spithoff; Lisa Bromley
Journal:  Can Fam Physician       Date:  2014-12       Impact factor: 3.275

Review 5.  The therapeutic potential of cannabis and cannabinoids.

Authors:  Franjo Grotenhermen; Kirsten Müller-Vahl
Journal:  Dtsch Arztebl Int       Date:  2012-07-23       Impact factor: 5.594

6.  Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review.

Authors:  Lauren Eadie; Lindsay A Lo; April Christiansen; Jeffrey R Brubacher; Alasdair M Barr; William J Panenka; Caroline A MacCallum
Journal:  Front Psychiatry       Date:  2021-03-12       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.